Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-302168S in Type 2 Diabetes Mellitus
NCT07755150Phase 2Not yet recruiting
- Sponsor
- Chengdu Diao Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of DA-302168S in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Chengdu Diao Pharmaceutical Group. Primary endpoint: Change from baseline in HbA1c at 16 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
DA-302168S
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07755150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07755150.